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Introduction
Venous thromboses cause high mortality in cancer patients 
[1, 2]. Prior studies conducted mainly on pediatric acute 
lymphoblastic leukemia (ALL) patients report associations 
of venous thromboses (VTs) with patient- (high body mass 
index (BMI), advanced age, comorbidities), disease- (ALL 
subtype), and treatment- related factors (asparaginase, ster-
oids, and intrathecal chemotherapy) [3–10]. Most VTs 
including cerebral venous thromboses (CVTs) in ALL 
patients occur during the first 2 or 3 months of leukemia 
treatment [3–5].
CVTs cover up to over 30% of all cases of VTs in 
ALL patients. It leads to dramatic consequences such as 
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Abstract
Cerebral venous thrombosis (CVT) covers up to a third of all venous throm-
boses (VTs) detected in patients with acute lymphoblastic leukemia (ALL). It 
usually hampers patients’ lives and may also endanger efficient leukemia treat-
ment. Although many factors have been suggested to account for an elevated 
risk of VTs in patients with ALL, there still is a lack of studies focusing on 
CVTs and especially in the setting of adult ALL patients. We studied in our 
retrospective population- based cohort the occurrence, characteristics, as well as 
risk factors for VTs in 186 consecutively diagnosed Finnish adult ALL patients 
treated with a national pediatric- inspired treatment protocol ALL2000. In the 
risk factor analyses for VTs we found a distinction of the characteristics of the 
patients acquiring CVT from those with other kinds of VTs or without throm-
bosis. In contrast to previous studies we were also able to compare the effects 
of asparaginase in relation to CVT occurrence. Notably, more than half of the 
CVTs were diagnosed prior the administration of asparaginase which accentuates 
the role of other risk factors on the pathophysiology of CVT compared to 
truncal or central venous line (CVL) VTs in adult ALL patients.
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epilepsy and cognitive or focal deficits in a significant 
amount of encountered patients [3, 6]. Etiological factors 
identified in nonleukemia patient cohorts include female 
sex, hormonal manipulation (e.g., oral contraceptives), 
certain malignancies, and head trauma, but they explain 
less than half of the CVT cases [11, 12]. Although CVT 
is a relatively common complication in ALL patients, we 
still do not know the specific biological basis of this event 
[3, 10].
CVTs may be hard to diagnose because the symptoms 
vary from mild headaches to life- threatening seizures or 
nausea with concomitant intracranial hypertension. The 
usual time lag between the onset of symptoms and diag-
nosis is about 2 weeks [11, 12].
Asparaginase is considered efficient and essential in ALL 
treatment. It depletes free asparagine and glutamine from 
the extracellular fluid. This leads to apoptosis of the malig-
nant lymphoblastic cells as their cell growth and division 
are highly dependent of these circulating amino acids [13]. 
Aside from the aimed antileukemic properties, asparaginase 
exposes patients to multiple adverse effects such as VTs. 
Other suspected, although not unanimously identified, risk 
factors of VTs in ALL patients include high BMI, T- cell 
ALL (T- ALL), and the concomitant use of steroids [14–17]. 
As to our knowledge, reports on whether the risk factors 
for CVTs and truncal or central venous line (VCL) VTs 
in ALL patients are alike, still lack.
We performed a population- based retrospective registry 
study on the Finnish ALL patients treated with a national 
ALL2000 study protocol during 2000–2012. We aimed to 
discover the potential distinction of the risk factors for 
CVTs and other VTs in ALL patients. Khorana score has 
been used for definition of patients in high risk of venous 
thrombosis in solid tumor malignancies [18]. In this study 
we also aimed to retrospectively monitor, whether basic 
laboratory tests and morphological factors detectable at 
ALL diagnosis could reveal patients in a high risk of a 
CVT.
Patients and methods
The study initially comprised of 201 consecutive adult 
ALL patients (aged 16–65 years) treated with a national 
protocol ALL2000 (results unpublished; MEA vs. CVAD 
as induction, CVAD as the first consolidation, and aspara-
ginase introduced in the second consolidation; Table 1) 
in the five Finnish university hospitals (Helsinki, Kuopio, 
Oulu, Tampere, and Turku) and Vaasa Central Hospital 
during 1999–2012. Patients were followed up to April 
2015 (median total follow- up: 4.2 years, range: 0.02–
14.9 years) after which the analysis was conducted. Patient 
consent was obtained according to the Declaration of 
Helsinki and the study was approved by the respective 
Ethics committee of each participating hospitals. Of 201 
patients, 186 were included in our analysis and 15 excluded 
by following criteria: insufficient patient records (n = 11), 
false primary diagnose (one lymphoma and one chronic 
lymphoblastic leukemia), and prior acute leukemia (n = 2) 
(Fig. S1).
In the ALL2000 study patients were randomized into 
two different induction groups, CVAD and MEA, after 
which they received identical consolidation therapies 
(Table 1). CVAD was given to 96 (52%) and MEA to 
90 (48%) of the patients. Escherichia coli- derived aspara-
ginase was introduced at 8th day of the second consoli-
dation block. In our study the median interval from the 
ALL diagnosis to the first actualized dose of asparaginase 
was 64 days (range: 43–196 days). Follow- up for the 
occurrence of VTs (median: 88 days, range: 7–219 days) 
was the time measured from leukemia diagnosis to the 
end of second consolidation block, allogeneic stem cell 
transplantation (alloSCT), or death. Primary endpoints of 
our study were a VT, alloSCT, or death. Only two of 
our study patients received prophylactic anticoagulation 
during leukemia treatment. Their indication for prophylaxis 
was atrial fibrillation.
The clinical phenotypes and basic laboratory values of 
the patients were recorded and included in our analysis. 
Detailed description of these parameters is shown in 
Table 2 and Table S1. All data were collected from patient 
charts. Only VTs confirmed by radiological imaging tech-
niques (ultrasound, computed tomography, or magnetic 
resonance imaging) were included in the analysis. Patient 
characteristic at the time of ALL diagnosis (Table 2), 
clinical characteristics of the VT patients (Table 3), and 
the data used in the analysis (Table S1) are shown.
Statistical analyses
SAS statistical software 9.3 (SAS Institute, Care, NC) and 
IBM SPSS statistics 22 were used for the statistical analysis. 
Mann–Whitney U or Pearson Chi- squared (χ2) tests were 
used in univariate analysis for patient characteristics 
depending on the data characteristics. Cox regression model 
was plotted with time- dependent covariate (asparaginase 
treatment) and the risk score model for CVT by using 
FREQ procedure. All analyses were two sided and P < 0.05 
was considered statistically significant.
Results
In total, 31 (17%) patients suffered from a VT, of whom 
nine (27%) had a CVT (Table 3). Other types of VTs 
(n = 22) included ten lower and one upper extremity 
deep venous thromboses, six central venous- line throm-
boses, and five pulmonary embolisms. The exact dates of 
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all VTs are shown on Table 1. CVTs occurred mostly at 
the first consolidation therapy which was earlier than other 
recorded VTs (median: 43 days, range: 34–126 and median: 
68 days, range: 1–127 and, respectively; P > 0.05).
A detailed description of the patient characteristics and 
distribution of them among leukemia or thrombosis sub-
types is given in Table 3. Distribution of CVAD or MEA 
induction among patients suffering from thrombosis during 
the follow- up is shown in Table 1.
The univariate analysis showed a significantly lower 
median BMI (21.5 kg/m2, range: 17.0–26.0 kg/m2) of CVT 
patients compared to patients with other VTs (P = 0.002) 
or without VTs (P = 0.018), respectively. Furthermore, 
CVT patients had more T- ALL (5/9, 56%) and extramed-
ullary leukemia (5/9, 56%) than patients with other VTs 
(3/22, (14%), P = 0.007 and 4/22, (18%), P = 0.037) 
and no VTs (23/155, (15%), P = 0.005 and 30/155, (19%), 
P = 0.010) (Table 3). CVT patients had a significantly 
higher CRP compared to patients with other VTs 
(P = 0.033), but a difference in leukocyte and platelet 
counts did not reach statistical significance (Table 3). 
Detailed characteristics of patients with CVTs are shown 
in Table 4. Most of the CVTs (5/9 (56%)) occurred before 
the first administration of asparaginase and we did not 
detect association of asparaginase with CVT in the Cox 
regression model (χ2: 0.000, P = 0.995). Lower BMI and 
T- ALL subtype remained significant factors in also this 
analysis (χ2: 3.926, P = 0.048 and χ2: 4.8708, P = 0.025, 
respectively). Of the CVT patients, 8/9 (89%) had been 
on oral steroids (dexamethasone), but none had received 
intrathecal chemotherapy (cytarabine or methotrexate) a 
week prior the thrombosis.
Patients with truncal or CVL VTs expressed typical 
general risk characteristics for VTs in the univariate 
analysis. They were older, had more comorbidities, and 
had a significantly higher median BMI (27.1 kg/m2, 
range: 20.2–39.5, P = 0.038) compared to patients with-
out VTs. (Table 3). Only 5/22 (32%) of the patients 
suffered from thrombosis before the first dosing of 
asparaginase and the Cox regression analysis showed a 
clear association of asparaginase treatment with occur-
rence of truncal or CVL VTs (χ2: 6.850, P = 0.0089). 
Furthermore, 21/22 (95%) received oral steroids and 
3/22 (14%) intrathecal treatment less than a week prior 
to the VT.
Extramedullary leukemia was found in 44 of 186 (24%) 
patients, and distribution of extramedullary leukemia is 
shown in Table S2. Of the nine CVT patients, two had 
a mediastinal tumor mass, two markedly enlarged lymph 
nodes, and one leukemic skin infiltration at diagnosis. 
Ninety- eight (53%) of all patients, 15 (48%) of patients 
with other VTs, and 5 (56%) of patients with a CVT 
were alive at the time the data were analyzed (Table S3). 
Most of all VTs (in total 52%) were diagnosed and treated 
in Helsinki University Hospital (Table S4). No statistically 
significant differences between the incidence rates of VTs 
were detected between the hospitals.
We also constructed a preliminary CVT risk score model 
based on our results, prior knowledge of CVT risk fac-
tors, and Khorana risk score model [11, 12, 18]. Age, 
gender, BMI, disease subtype, leukemia dissemination, 
hemoglobin, and platelet counts at ALL diagnosis were 
included in the score. Ranking limits (0 or 1 point/param-
eter) were selected according to the association study 
results previously published [18]. A risk score of ≥5 points 
equals to a high risk for CVT (Fig. 1). Patients in the 
high- risk group represented more than 20- fold risk for 
CVT compared to the patients in the low- risk group 
(hazard ratio = 20.841, P < 0.0001, 95% CI: 5.208–83.401). 
The score model showed an excellent specificity and a 
moderate sensitivity (NPV: 0.982, PPV: 0.375).
Discussion
Venous thromboses often compromise the effective treat-
ment of ALL. We performed a detailed analysis of the 
occurrence and risk factors for VTs in a consecutive series 
of adult patients diagnosed in Finland in 2000–2012 and 
treated according to a national study protocol ALL2000. 
The incidence rates of VTs were comparable to previous 
reports [10, 12, 15–17]. Risk factors for truncal or CVL 
VTs were as hypothesized and reflected many of the tra-
ditional hazards for thrombosis detected in the general 
population. These factors, however, were distinct from 
those detected in patients with CVT in our study cohort.
Namely, patients acquiring CVT were younger and had 
a statistically significantly lower BMI and higher incidences 
of extramedullary and T- cell leukemia compared to patients 
with no VTs and truncal or CVL VTs. A study made by 
Zuurbier et al. showed no differences in age (median 33 
vs. 33 years) between CVT and no CVT patients, whereas 
CVT patients in a study conducted by Couturier et al. 
showed age distribution (median 29 vs. 33 years) near 
to our results but without a statistical significance [14, 
15]. In comparison to our results these discrepancies may 
be explained by a different age distribution of the patient 
population (16–65 and 16–18 to 59 years, respectively). 
Young age as risk factor for CVT is supported by the 
review by McBane et al., where median of the patients 
receiving CVT were at the age of early forties [11]. The 
distinctively low BMI in CVT patients in our analysis is 
likely explained by the young age of the affected patients.
CVT is a severe complication that may lead to difficult 
sequelae [11, 12, 14]. It often causes delays or truncations 
in the treatment of ALL. Hence, we think that clinicians 
should be aware that not only the overweighed and older 
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patients are at risk of a serious thrombotic complications. 
As delays in diagnoses of CVTs are frequent our results 
may also carry on impact in sensitizing clinicians to order 
proper radiological investigations for patients with neu-
rological symptoms.
Mediastinal mass may increase the risk of thrombosis 
by, for example, increasing mediastinal pressure that could 
impair venous flow from the cerebral veins [6]. Two (22%) 
of the nine CVT patients (Table 4) had a mediastinal 
mass at ALL diagnosis in our study. Due to the limited 
number of the study patients, the etiological role of these 
masses in CVT occurrence cannot be estimated. Compared 
to the ALL- subtype distribution of all ALL2000 patients 
(Table 2 and Table 3) our CVT patients had 3.3- fold 
incidence of T- ALL. This is more than reported previously 
(2- and 1.5- fold) [14, 15]. T- ALL is more frequent in 
males which likely explains the even distribution of our 
CVT cases between genders in our analysis. T- ALL is also 
Table 1. Occurrence of venous thromboses in the ALL2000 cytostatic treatment. This table shows the cytostatic protocol and the time of venous  
thrombosis (VT) diagnosis in the first three treatment blocks of the ALL2000 study. Intrathecal cytostatic and asparaginase treatments are  
highlighted with colors (light orange and light red, respectively). Patients with venous thromboses (VTs, numbers represent patient codes) are also  
highlighted with colors that are explained in the footnote.
Cytostatic agents 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 Cumulative doses/m²
MEA induction
Mitoxantrone i.v. ↑ ↑ ↑ ↑ 60 mg
Etoposide i.v. ↑ ↑ ↑ ↑ 400 mg
Cytarabine i.v. ↑↑ ↑↑ ↑↑ ↑↑ 8000 mg/4000 mg
Methotrexate i.t. 1± ↑ 1± ↑4 25 mg
Cytarabine i.t. ↑4 75 mg
CVAD induction
Cyclophosphamide i.v. ↑↑ ↑↑ ↑↑ ↑↑ ↑ 3600 mg
Vincristine i.v. ↑ ↑ 42 mg
Doxorubicin i.v. ↑ 50 mg
DEXA p.o. ↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑ 160 mg
Methotrexate i.t. 1± ↑ 1± ↑4 25 mg
Cytarabine i.t. ↑4 75 mg
VTs 4081,3
4553
4561,2
First cons. therapy
Cyclophosphamide i.v. ↑↑ ↑↑ ↑↑ ↑↑ ↑ 3600 mg
Vincristine i.v. ↑ ↑ 42 mg
Doxorubicin i.v. ↑ 50 mg
DEXA p.o. ↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑ 160 mg
Methotrexate i.t. ↑4 12.5 mg
Cytarabine i.t. ↑4 75 mg
VTs 521,2 3511,3 1103 1191,3 1153 1213 1221,2
1651,2
24 28
Second cons. therapy
Daunorubicin i.v. ↑ ↑ ↑ 180 mg/135 mg
Vincristine i.v. ↑ ↑ ____ ____ ____ ____ 2.8 mg/m² + 1.6 mg
DEXA p.o. ↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑ 160 mg
Asparaginase i.v. ↑ ↑ ↑ ↑ ↑4 30 000 IU/20 000 IU
Cytarabine i.t. ↑4 75 mg
VTs 1321,2 5262 5121,3 3072 1311,3 1352 2132 2312
1531,3 1621,3 6012 582 1302 5112 4493 1091,2
4201,3 4581,2 1571,3 3142
In case of two different doses, the first one for patients <56 years and the last one for patients >56 years of age. 1 ± : 1 dose given in one of  
these 3 days; ↑: one dose daily; ↑↑: two doses daily. , Cerebral venous thrombosis; , Lower extremity thrombosis; , Central venous- line  
thrombosis; , Upper extremity thrombosis; , Pulmonary embolism.
Cons., consolidation.
1Patients who were dead at the time the data were analyzed.
2CVAD.
3MEA.
4Drug given only, when platelet count > 40 × 10ˆ9.
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recurrently associated with an inferior outcome of ALL 
[19]. These factors—age, BMI, extramedullary leukemia, 
and T- ALL—together with the prechemotherapy trend of 
low platelet and high leukocyte counts might reflect an 
aggressive form of leukemia that potentially and specifi-
cally predisposes patients for CVTs. Unfortunately, neither 
detailed genomic data on inherited factors affecting patients’ 
potential thrombophilia were available nor biobank samples 
collected due to technical limitations in the molecular 
genetic diagnostics during the era of ALL2000 data 
collection.
Contrary to current consent, over half (56%) of the 
patients suffered from CVT before the introduction of 
asparaginase in our study cohort [10]. In addition, two 
of the nine CVT patients suffered from prodromal symp-
toms before the first dose of asparaginase (problems with 
gait n = 1, persistent headaches n = 1) (Table 3). This 
could have reflected an already ongoing thrombotic 
Table 1. Occurrence of venous thromboses in the ALL2000 cytostatic treatment. This table shows the cytostatic protocol and the time of venous  
thrombosis (VT) diagnosis in the first three treatment blocks of the ALL2000 study. Intrathecal cytostatic and asparaginase treatments are  
highlighted with colors (light orange and light red, respectively). Patients with venous thromboses (VTs, numbers represent patient codes) are also  
highlighted with colors that are explained in the footnote.
Cytostatic agents 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 Cumulative doses/m²
MEA induction
Mitoxantrone i.v. ↑ ↑ ↑ ↑ 60 mg
Etoposide i.v. ↑ ↑ ↑ ↑ 400 mg
Cytarabine i.v. ↑↑ ↑↑ ↑↑ ↑↑ 8000 mg/4000 mg
Methotrexate i.t. 1± ↑ 1± ↑4 25 mg
Cytarabine i.t. ↑4 75 mg
CVAD induction
Cyclophosphamide i.v. ↑↑ ↑↑ ↑↑ ↑↑ ↑ 3600 mg
Vincristine i.v. ↑ ↑ 42 mg
Doxorubicin i.v. ↑ 50 mg
DEXA p.o. ↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑ 160 mg
Methotrexate i.t. 1± ↑ 1± ↑4 25 mg
Cytarabine i.t. ↑4 75 mg
VTs 4081,3
4553
4561,2
First cons. therapy
Cyclophosphamide i.v. ↑↑ ↑↑ ↑↑ ↑↑ ↑ 3600 mg
Vincristine i.v. ↑ ↑ 42 mg
Doxorubicin i.v. ↑ 50 mg
DEXA p.o. ↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑ 160 mg
Methotrexate i.t. ↑4 12.5 mg
Cytarabine i.t. ↑4 75 mg
VTs 521,2 3511,3 1103 1191,3 1153 1213 1221,2
1651,2
24 28
Second cons. therapy
Daunorubicin i.v. ↑ ↑ ↑ 180 mg/135 mg
Vincristine i.v. ↑ ↑ ____ ____ ____ ____ 2.8 mg/m² + 1.6 mg
DEXA p.o. ↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑ 160 mg
Asparaginase i.v. ↑ ↑ ↑ ↑ ↑4 30 000 IU/20 000 IU
Cytarabine i.t. ↑4 75 mg
VTs 1321,2 5262 5121,3 3072 1311,3 1352 2132 2312
1531,3 1621,3 6012 582 1302 5112 4493 1091,2
4201,3 4581,2 1571,3 3142
In case of two different doses, the first one for patients <56 years and the last one for patients >56 years of age. 1 ± : 1 dose given in one of  
these 3 days; ↑: one dose daily; ↑↑: two doses daily. , Cerebral venous thrombosis; , Lower extremity thrombosis; , Central venous- line  
thrombosis; , Upper extremity thrombosis; , Pulmonary embolism.
Cons., consolidation.
1Patients who were dead at the time the data were analyzed.
2CVAD.
3MEA.
4Drug given only, when platelet count > 40 × 10ˆ9.
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process. Unlike ALL2000 protocol, most current ALL treat-
ment protocols introduce asparaginase at induction. These 
types of study settings might therefore partly overweight 
the causal role of asparaginase for CVTs. Our results 
demonstrate for the first time a minor associative role 
of asparaginase treatment on the occurrence of CVT. The 
analysis is unique because it enabled us to study the risk 
factors of an early occurring CVT in adult ALL patients 
without the effect of asparaginase during the first two 
treatment blocks where the risk of CVT is at the highest. 
We suggest that this novel finding further strengthens the 
idea of the differences in pathophysiology of CVT, and 
truncal or CVL- related thrombosis. We also suggest that 
ALL disease itself might play a bigger role in the devel-
opment of CVT than thought before.
Central nervous system (CNS) malignancies and intrath-
ecal chemotherapy may contribute to the risk of CVT 
development, by, for example, increasing the brain tissue 
prothrombin levels, or by damaging the blood–brain bar-
rier [11, 14]. None of our patients had received intrathecal 
chemotherapy shortly before the thrombosis (Table 3). 
Although none of our CVT patients had a detectable 
CNS leukemia in the morphological analysis of the cer-
ebrospinal fluid, it is still possible that a minimal, occult 
CNS leukemia could account for an increased risk of 
CVT. Regrettably, antithrombin levels that have been 
shown to increase the risk of thrombosis were not rou-
tinely collected at the time of patient enrolment in this 
study [9]. A recent study on acute myeloid leukemia 
patients suggests that a situation parallel with disseminated 
intravascular coagulopathy (i.e., low platelet count, low 
TT%, and high D- dimer) could increase the risk of venous 
thrombosis [20]. Unfortunately, although our CVT 
patients showed a decreased level of platelets and elevated 
Table 2. Patient characteristics at ALL diagnosis. Patients were divided according to ALL disease subtypes.
Patients All (n = 186) pre- B (n = 118) Ph+ (n = 37) T (n = 31)
Variables Yes, n (%)/Median 
(range)
Yes, n (%)/Median 
(range)
Yes, n (%)/Median 
(range)
Yes, n (%)/
Median (range)
Gender (Male) 111 (60) 71 (60) 20 (54) 21 (65)
Age 40.9 (16.1- 65.8) 39.9 (16.1- 65.8) 48.9 (19.2- 64.6) 35.6 (17.0- 61.5)
BMI 25.5 (17.0- 46.5) 25.5 (17.5- 46.5) 25.7 (19.7- 40.3) 25.0 (17.0- 39.5)
Extramedullary leukemia 44 (24) 21 (18) 3 (9) 19 (61)
Abdomen, mediastinum, skin, and/
or lymph nodes 
39 (21) 18 (16) 2 (5) 19 (61)
CNS leukemia 4 (3) 3 (2) 1 (3) 0 (0)
Prior comorbidities 
No comorbidities 118 (64) 70 (60) 24 (65) 24 (77)
At least one comorbidity 66 (36) 46 (40) 13 (35) 7 (23)
Hypertension 18 (10) 15 (13) 2 (5) 1 (3)
Hypercholesterolemia 12 (6) 10 (8) 2 (5) 0 (0)
Diabetes 10 (5) 7 (6) 2 (5) 1 (3)
Asthma 7 (4) 6 (5) 0 (0) 1 (3)
Thyroid disorder 7 (4) 4 (3) 3 (8) 0 (0)
Atrial fibrillation 2 (1) 0 (0) 2 (5) 0 (0)
Myocardial infarction 3 (2) 3 (3) 0 (0) 0 (0)
Epilepsy 3 (2) 2 (2) 0 (0) 1 (3)
Ulcerative colitis 4 (2) 4 (3) 0 (0) 0 (0)
Previous cancer 7 (4) 4 (3) 3 (8) 0 (0)
Prior venous thrombosis 2 (1) 2 (2) 0 (0) 0 (0)
Other factors
Smoking (current/prior) 32 (17) 18 (15) 6 (16) 8 (26)
Infection less than a week prior to 
ALL diagnosis
21 (12) 12 (10) 4 (12) 5 (16)
BMI > 30 31 (17) 23 (21) 4 (11) 4 (13)
Hormonal therapy (progestin/
estrogen) at diagnosis
6 (3) 3 (3) 1 (3) 2 (6)
Anticoagulation at diagnosis 3 (2) 2 (2) 1 (3) 0 (0)
Philadelphia- positive (Ph+) patients were statistically significantly older than precursor B- ALL (pre- B) and T- ALL (T) patients (P = 0.032 and P = 0.009, 
respectively). T- ALL patients had significantly more extramedullary leukemia compared to other disease subtypes (χ2: 31.984, P = 0.001). No further 
statistically significant differences between ALL subtypes were detected in other patient characteristics.
BMI, body mass index; CNS, Central nervous system.
1281© 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
Minor Role of Asparaginase in CVT in Adult ALLS. Roininen et al.
Ta
b
le
 3
. C
lin
ic
al
 c
ha
ra
ct
er
is
tic
s 
of
 p
at
ie
nt
s 
w
ith
 v
en
ou
s 
th
ro
m
bo
se
s.
Ty
pe
 o
f 
ev
en
t 
va
ria
bl
es
N
o 
ve
no
us
 
th
ro
m
bo
si
s 
(n
 =
 1
55
)
A
ll 
ve
no
us
 
th
ro
m
bo
se
s 
(n
 =
 3
1)
O
th
er
 v
en
ou
s 
th
ro
m
bo
se
s 
(n
 =
 2
2)
C
V
Ts
 (n
 =
 9
)
A
ll 
vs
. n
o 
ve
no
us
 
th
ro
m
bo
se
s
O
th
er
 v
s.
 n
o 
ve
no
us
 
th
ro
m
bo
se
s
C
V
Ts
 v
s.
 n
o 
ve
no
us
 
th
ro
m
bo
se
s
C
V
Ts
 v
s.
 
ot
he
r 
ve
no
us
 
th
ro
m
bo
se
s
Pr
ec
he
m
ot
he
ra
py
 la
bo
ra
to
ry
 v
al
ue
s
M
ed
ia
n 
(r
an
ge
)
M
ed
ia
n 
(r
an
ge
)
M
ed
ia
n 
(r
an
ge
)
M
ed
ia
n 
(r
an
ge
)
P-
 va
lu
e
P-
 va
lu
e
P-
 va
lu
e
P-
 va
lu
e
H
em
og
lo
bi
n
94
.5
 (3
5–
17
2)
10
6 
(3
9–
15
9)
10
7 
(6
8–
15
9)
10
5 
(3
9–
13
6)
0.
16
3
0.
26
5
0.
30
7
0.
69
5
Pl
at
el
et
s
56
.0
 (4
–4
45
)
56
.0
 (3
–2
91
)
57
.5
 (7
–2
91
)
35
.0
 (3
–2
04
)
0.
86
9
0.
69
7
0.
30
9
0.
30
6
Le
uk
oc
yt
es
11
.0
 (0
.6
–3
07
)
17
.9
 (1
.3
–2
37
)
16
.3
 (1
.3
–2
37
)
18
.9
 (2
–2
21
)
0.
33
3
0.
64
2
0.
26
9
0.
50
0
C
RP
18
.5
 (1
–4
19
))
17
.0
 (2
–2
21
)
12
.0
 (2
–1
39
)
43
.0
 (2
–2
21
)
0.
86
3
0.
23
6
0.
12
3
0.
03
3
D
- D
im
er
1.
80
 (0
.0
2–
97
)
2.
80
 (0
.1
–7
1)
2.
40
 (0
.2
–1
2)
5.
40
 (0
.1
–7
1)
0.
53
9
0.
89
9
0.
31
8
0.
23
6
B-
 bl
as
ts
4.
70
 (0
–2
60
)
11
.6
 (0
–2
19
)
8.
30
 (0
–2
19
)
13
.7
 (0
–2
17
)
0.
43
1
0.
74
6
0.
30
0
0.
49
7
Pa
tie
nt
 a
nd
 d
is
ea
se
 c
ha
ra
ct
er
is
tic
s
A
ge
41
.2
 (1
6.
1–
56
.4
)
40
.6
 (1
8.
2–
65
.3
)
43
.6
 (1
8.
2–
65
.3
)
27
.1
 (1
8.
6–
58
.2
)
0.
85
2
0.
27
5
0.
16
6
0.
05
6
BM
I
25
.5
 (1
7.
5–
46
.5
)
25
.3
 (1
7.
0–
39
.5
)
27
.0
 (2
0.
2–
39
.5
)
21
.5
 (1
7.
0–
26
.0
)
0.
67
3
0.
03
8
0.
01
8
0.
00
2
G
en
de
r,
 M
al
e,
 n
 (%
)
95
 (6
1)
17
 (5
5)
13
 (6
2)
4 
(4
4)
0.
54
7
0.
90
7
0.
33
5
0.
45
7
D
is
ea
se
 s
ub
gr
ou
ps
Y
es
, n
 (%
)
Y
es
, n
 (%
)
Y
es
, n
 (%
)
Y
es
, n
 (%
)
pr
ec
ur
so
r 
B-
 ce
ll 
A
LL
98
 (6
3)
20
 (6
5)
18
 (8
2)
2 
(2
2)
Ph
ila
de
lp
hi
a-
 po
si
tiv
e 
B-
 ce
ll 
A
LL
34
 (2
2)
3 
(1
4)
1 
(5
)
2 
(2
2)
T-
 ce
ll 
A
LL
23
 (1
5)
8 
(3
8)
3 
(1
4)
5 
(5
6)
0.
14
8
0.
14
8
0.
00
5
0.
00
7
Ex
tr
am
ed
ul
la
ry
 le
uk
em
ia
30
 (1
9)
9 
(3
0)
4 
(1
8)
5 
(5
6)
0.
22
7
0.
94
2
0.
01
0
0.
03
7
C
N
S 
le
uk
em
ia
4 
(3
)
0 
(0
)
0 
(0
)
0 
(0
)
0.
36
6
0.
44
4
0.
62
6
≥ 
1 
C
om
or
bi
di
tie
s
51
 (3
3)
15
 (4
8)
12
 (5
5)
3 
(3
3)
0.
11
1
0.
05
3
1.
00
0
0.
28
3
Sm
ok
in
g 
hi
st
or
y
24
 (1
6)
8 
(2
6)
6 
(2
7)
3 
(3
3)
0.
08
0
0.
18
3
0.
17
1
0.
21
0
In
fe
ct
io
n 
at
 d
ia
gn
os
is
16
 (1
1)
5 
(1
7)
3 
(1
4)
2 
(2
9)
0.
32
7
0.
69
5
0.
15
2
0.
36
2
Tr
ea
tm
en
t-
 as
so
ci
at
ed
 f
ac
to
rs
 a
t 
ve
no
us
 t
hr
om
bo
si
s
D
ay
 o
f 
th
e 
th
ro
m
bo
si
s
68
 (0
–2
17
)
43
 (3
4–
12
6)
0.
34
9
C
en
tr
al
 v
en
ou
s-
 lin
e 
ca
th
et
er
 a
t 
th
ro
m
bo
si
s
8 
(4
4)
4 
(4
4)
1.
00
0
A
sp
ar
ag
in
as
e 
be
fo
re
 t
hr
om
bo
si
s
15
 (6
8)
4 
(4
4)
0.
21
8
In
tr
at
he
ca
l c
he
m
ot
he
ra
py
 a
 w
ee
k 
be
fo
re
 t
hr
om
bo
si
s
3 
(1
4)
0 
(0
)
0.
24
4
D
ex
am
et
ha
so
ne
 a
 w
ee
k 
be
fo
re
 t
hr
om
bo
si
s
21
 (9
5)
9 
(1
00
)
0.
51
6
BM
I, 
Bo
dy
 m
as
s 
in
de
x;
 C
V
T,
 C
en
tr
al
 v
en
ou
s 
th
ro
m
bo
si
s.
1282 © 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
S. Roininen et al.Minor Role of Asparaginase in CVT in Adult ALL
Ta
b
le
 4
. C
ha
ra
ct
er
is
tic
 o
f 
pa
tie
nt
s 
w
ith
 c
er
eb
ra
l v
en
ou
s 
th
ro
m
bo
se
s.
Pa
tie
nt
 c
ha
ra
ct
er
is
tic
s 
an
d 
la
bo
ra
to
ry
 v
al
ue
s 
at
 d
ia
gn
os
is
C
ha
ra
ct
er
is
tic
s 
of
 C
V
Ts
Tr
ea
tm
en
t-
 re
la
te
d 
fa
ct
or
s
N
b
Se
x
D
ay
^
D
is
ea
se
 
su
bt
yp
e
EM
 
di
s-
ea
se
C
N
S 
le
u-
ke
m
ia
A
ge
BM
I
Pl
ts
H
b
Le
uk
C
RP
D
- d
im
er
Sy
m
pt
om
s
Si
te
Im
ag
in
g
A
SP
D
EX
A
^
^
It.
 
th
er
ap
y^
^
1
F
34
Ph
+
N
o
N
o
41
.0
23
.6
3
98
9.
8
18
6
71
Ri
gh
t 
he
m
ip
ar
es
is
, 
ve
rt
ig
o,
 s
pe
ec
h 
de
fic
it1
SS
S,
 le
ft
 
tr
an
sv
 er
se
 
si
nu
s
M
RI
N
ev
er
Y
es
N
o
2
F
39
pr
e-
 B
N
o
N
o
20
.8
21
.5
27
39
18
.9
4
0.
1
H
ea
da
ch
e1
SS
S
C
T 
+
 
M
RI
N
ev
er
Y
es
N
o
3
M
43
T
Y
es
N
o
20
.7
19
.6
20
4
12
5
2
10
0.
2
Le
ft
 h
em
ip
ar
es
is
, 
se
iz
ur
es
, h
ea
da
ch
e1
SS
S
M
RI
N
ev
er
Y
es
N
o
4
F
43
pr
e-
 B
Y
es
N
o
26
.3
20
.4
72
10
5
22
1
73
5.
9
N
um
bn
es
s 
of
 t
he
 le
ft
 
ar
m
, f
ac
e,
 a
nd
 t
on
gu
e1
C
or
tic
al
 v
ei
ns
M
RI
′N
ev
er
Y
es
N
o
5
M
73
T
Y
es
N
o
37
.0
23
.7
22
85
35
.7
23
35
Le
ft
 h
em
ip
ar
es
is
 a
nd
 
nu
m
bn
es
s 
of
 t
he
 le
ft
 
si
de
1
SS
S
M
RI
Y
es
Y
es
N
o
6
M
50
T
Y
es
N
o
27
.1
21
.0
78
12
0
3.
8
13
1
5.
9
H
ea
da
ch
e1
SS
S,
 v
en
ou
s 
in
fa
rc
tio
ns
M
RI
Y
es
Y
es
N
o
7
F
65
T
N
o
N
o
18
.5
17
.0
74
11
3
18
8
33
5.
4
N
um
bn
es
s 
an
d 
pa
re
si
s 
of
 t
he
 le
ft
 a
rm
2
SS
S
C
T 
+
 
M
RI
Y
es
Y
es
N
o
8
F
42
Ph
+
N
o
N
o
48
.2
26
.0
35
13
6
64
.4
22
1
0.
5
Ri
gh
t 
he
m
ip
ar
es
is
, 
sp
ee
ch
 d
efi
ci
t2
SS
S,
 c
or
tic
al
 
ve
in
s,
 
he
m
or
rh
ag
e
C
T 
+
 
M
RI
N
ev
er
N
o
N
o
9
M
12
6
T
Y
es
N
o
40
.2
25
.4
30
10
4
15
43
3.
6
H
ea
da
ch
e,
 f
at
ig
ue
SS
S,
 s
in
us
 
re
ct
us
M
RI
Y
es
Y
es
N
o
N
b,
 p
at
ie
nt
 n
um
be
r;
 D
ay
^
, n
um
be
r 
of
 d
ay
s 
be
tw
ee
n 
A
LL
 d
ia
gn
os
is
 a
nd
 t
he
 C
V
T;
 E
M
, e
xt
ra
m
ed
ul
la
ry
; C
N
S,
 c
en
tr
al
 n
er
vo
us
 s
ys
te
m
; B
M
I, 
bo
dy
 m
as
s 
in
de
x;
 P
lt,
 p
la
te
le
t 
co
un
t;
 H
b,
 h
em
og
lo
bi
n;
 L
eu
k,
 
le
uk
oc
yt
es
; 
A
SP
, 
as
pa
ra
gi
na
se
; 
D
EX
A
, 
de
xa
m
et
ha
so
ne
; 
I.t
., 
in
tr
at
he
ca
l; 
^
^
, 
le
ss
 t
ha
n 
a 
w
ee
k 
be
fo
re
 t
he
 C
V
T.
 P
ar
am
et
er
s 
us
ed
 in
 t
he
 t
ab
le
: 
F,
 f
em
al
e;
 M
, 
m
al
e;
 P
h+
, 
Ph
ila
de
lp
hi
a-
 po
si
tiv
e 
A
LL
; 
pr
e-
 B,
 
pr
ec
ur
so
r 
B-
 A
LL
; T
, T
- A
LL
.
1 P
ro
dr
om
al
 s
ym
pt
om
s
2 P
ro
dr
om
al
 s
yn
dr
om
es
 t
ha
t 
oc
cu
rr
ed
 b
ef
or
e 
th
e 
in
tr
od
uc
tio
n 
of
 a
sp
ar
ag
in
as
e;
 S
SS
: s
up
er
io
r 
sa
gi
tt
al
 s
in
us
; M
RI
: m
ag
ne
tic
 r
es
on
an
ce
 im
ag
in
g;
 a
nd
 C
T:
 c
om
pu
te
r 
to
m
og
ra
ph
y.
1283© 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
Minor Role of Asparaginase in CVT in Adult ALLS. Roininen et al.
level of D- dimer, no TT% was measured at the time of 
ALL diagnosis. This idea could not therefore be evaluated 
in our cohort.
Based on Khorana risk score model, results obtained in 
our study, and the knowledge of common CVT risk fac-
tors, we built a preliminary risk score model for CVT [11, 
12, 18]. Retrospective study design and limited number of 
patients, however, restrict our analysis and it therefore needs 
to be validated in a larger and prospective study cohort.
Our study is probably the first one to analyze dif-
ferences in potential risk factors of a CVT compared 
with patient groups of both no VTs and with other 
VTs in adult ALL. Surprisingly, asparaginase treatment 
did not show association with the occurrence of CVTs 
in our study setting. Patients with a CVT were also 
leaner and younger than other subjects. We suggest that 
rather than imputed acquired risk factors for VTs, such 
as asparaginase, the characteristics of the ALL disease 
itself might play a significant role in the development 
of CVT in adult ALL patients. We think that more 
studies aiming at validation of an individualized CVT 
risk estimation in ALL patients are needed for. Genetic 
factors related both to leukemia and inherited throm-
bophilia should also be investigated and potentially taken 
into account.
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Figure 1. Risk score model for cerebral venous thrombosis. (A) Shows graphics of the risk score model for cerebral venous thrombosis (CTV) where 
CVT patients (light gray bars, n = 9) are compared to patients without CVT (dark gray bars, n = 177) at the time of ALL diagnosis. Percentages of 
amount of patients belonging to each risk group (x- axis) are shown on the y- axis. Of CVT and no CVT patients, 6/9 (67%) and 10/177 (6%) scored ≥ 
5 points (high- risk group), respectively. (B) Shows variables and cut- offs used in the risk score model for CVT. Cut- offs with P- value < 0.05 were used. 
Hemoglobin cut- off was based on Khorana risk score model [15] and female sex based on the female dominance in the CVT cases [9].
Variables Cut-offs Risk values -values P-values
Hemoglobin > 100 g/L 1p 1.421 0.233
Platelet count <80 x 10 9 1p 3.140 0.076
Sex Female 1p 0.912 0.340
Age <41 years 1p 5.019 0.025
BMI < 4 kg/m2 1p 5.634 0.018
Disease subtype T-ALL 1p 11.141 0.004
Leukemia 
dissemination
Extramedullary 
leukemia
1p 5.599 0.018
Risk groups Abbreviation Cut-off
Low-risk LR <5p
High-risk HR 5p
A
B
2
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Supporting Information
Additional supporting information may be found in the 
online version of this article:
Figure S1. Patients enrolled at the study. ALL: acute 
lymphoblastic leukemia; CCL: chronic lymphoblastic 
leukemia.
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Table S1. Data used in the ALL analysis.
Table S2. Distribution of extramedullary leukemia among 
ALL patients. Sites and the incidence rate of extramedul-
lary leukemia are shown on the table. In case of several 
extramedullary sites, central nervous system (CNS- ) leu-
kemia, mediastinal mass, spleen and lymph nodes were 
considered as the major site of an extramedullary leukemia. 
The column proportions do not differ significantly from 
each other at the 0.05 level. VT: venous thrombosis, CVT 
cerebral venous thrombosis, CVL: central venous line.
Table S3. Survival of patients in different groups. The 
column proportions do not differ significantly from each 
other at the 0.05 level. VT: venous thrombosis, CVT cer-
ebral venous thrombosis, CVL: central venous line.
Table S4. Distribution of venous thromboses in different 
hospitals. Each subscript letter denotes a subset of Hospital 
categories whose column proportions do not differ sig-
nificantly from each other at the 0.05 level. VT: venous 
thrombosis, CVT cerebral venous thrombosis, CVL, central 
venous line.
